-
Deutsche Bank Lowers PT on CR Bard To $98
Friday, July 22, 2011 - 7:38am | 27Deutsche Bank has lowered the price target on CR Bard (NYSE: BCR) from $100 to $98 and maintains its Hold rating.
-
Bank of America Downgrades CR Bard To Neutral, $115 PO
Friday, July 22, 2011 - 7:36am | 26Bank of America has downgraded CR Bard (NYSE: BCR) from Buy to Neutral and maintains its $115 price objective.
-
UPDATE: Morgan Stanley Raises PT on Baxter International from $58 to $63
Friday, July 22, 2011 - 7:34am | 234Morgan Stanley has published a report on Baxter International (NYSE: BAX) raising the price target from $58.00 to $63.00. In the report, Morgan Stanley wrote, "Another strong quarter with improving margins and EPS growth increases visibility on upside to 2H11 and 2012 estimates. Baxter's guidance...
-
Bank of America Merrill Lynch Maintains Neutral on Edwards Lifesciences
Friday, July 22, 2011 - 7:28am | 126Bank of America Merrill Lynch is out with its report today on Edwards Lifesciences (NYSE: EW), maintaining Neutral. In a note to clients, Bank of America Merrill Lynch writes, "Over the next five-plus years, there is no other new product opportunity in medtech of a similar potential size as the...
-
Morgan Stanley Comments on C.R. Bard Amid Litigation
Friday, July 22, 2011 - 7:15am | 149Morgan Stanley has published a report on C.R. Bard (NYSE: BCR). In the report, Morgan Stanley wrote, "After a strong 1Q11, Bard discussed managing down to meet their 14% earnings growth obligation. Now, after a pressured 2Q11, they may need to manage EPS up. Even if organic revenue does not...
-
Morgan Keegan Reiterates Outperform and PT of $115 on C.R. Bard
Friday, July 22, 2011 - 7:09am | 62Morgan Keegan reiterated its Outperform rating on C.R. Bard (NYSE: BCR). At the same time, the rating agency left its price target on the company's stock unchanged at $115. On Thursday, BCR added 0.6% to its value to finish the day at $112.71. In today's pre-market trading, its shares lost 6.08% of...
-
Citi Comments on Edwards Lifesciences Corp Before Product Launch
Friday, July 22, 2011 - 6:59am | 151Citi has published a report on Edwards Lifesciences Corp (NYSE: EW) anticipating the launch of the SAPIEN system in the 4Q. In the report, Citi wrote, "EW reported 2Q11 operating EPS of $0.49 (+7%), in line with our estimate but $0.01 below consensus. Notably, mgmt chose not to exclude a $2M IPR...
-
JP Morgan Raises PT On Baxter International To $64
Friday, July 22, 2011 - 6:54am | 27JP Morgan has raised the price target on Baxter International (NYSE: BAX) from $60 to $64 and maintains its Neutral rating.
-
Morgan Stanley Raises PT On Baxter International to $63
Friday, July 22, 2011 - 5:58am | 27Morgan Stanley has raised the price target on Baxter International (NYSE: BAX) from $58 to $63 and maintains its Overweight rating.
-
After Hours Earnings Movers
Thursday, July 21, 2011 - 4:53pm | 113A number of companies reported earnings on Thursday after the closing bell. Here is a look at the biggest movers. Cepheid (NASDAQ: CPHD) +9.07% to $34.50 Athenahealth (NASDAQ: ATHN) +9.10% to $53.00 Ruby Tuesday (NYSE: RT) -8.60% to $10.10 Acme Packet (NASDAQ: APKT) -8.09% to $55.25 C.R. Bard...
-
Edwards Lifesciences Bid Lower on Earnings Results
Thursday, July 21, 2011 - 4:43pm | 156Shares of Edwards Lifesciences (NYSE: EW) are bid lower in the after-hours following the release of the company's Q2 earnings results. Currently, shares are bid $81.27, at $82.00; they ended the regular session lower by 5.69%, at $82.55. Edwards Lifesciences said that Q2 EPS came in at $0.49 on...
-
Calls Purchased on Thoratec
Thursday, July 21, 2011 - 10:59am | 112Shares of Thoratec (NASDAQ: THOR) are higher on the session by 1.10%, currently trading at $36.63. The stock has been moving largely higher over the past five months and is currently trading above the 50-day moving average. Options traders are buying calls on the name today. A short while ago the...
-
Citi Maintains Sell on St. Jude Medical
Thursday, July 21, 2011 - 9:19am | 86Citi is out with its report today on St. Jude Medical (NYSE: STJ), maintaining Sell. In a note to clients, Citi writes, "2Q11 results made it clear to us that bullish commentary on share gains and new products is not going to drive results anytime soon with 55% of sales tied to a struggling CRM...
-
Biggest Losers in Pre-Market Trading
Thursday, July 21, 2011 - 9:00am | 93Travelzoo (NASDAQ: TZOO) is down over 23% after reporting disappointing Q2 earnings. Seagate Tech (NASDAQ: STX) is down over 14% after reporting earnings Wednesday afternoon. Meridian Bioscience (NASDAQ: VIVO) is down over 12% after reporting earnings. Genworth Financial (NYSE: GNW) is down over...
-
J.P. Morgan Reiterates Overweight Rating On Xilinx
Thursday, July 21, 2011 - 8:32am | 81According to J.P. Morgan, Xilinx (NYSE: EW) reported June quarter results above expectations and provided seasonal September quarter guidance. J.P. Morgan said that it would remain buyers of XLNX stock as the reasons it upgraded remain intact: the end of the inventory correction and its...